Cargando…
Antibody–Drug Conjugates for Cancer Therapy
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity t...
Autores principales: | Hafeez, Umbreen, Parakh, Sagun, Gan, Hui K., Scott, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587605/ https://www.ncbi.nlm.nih.gov/pubmed/33081383 http://dx.doi.org/10.3390/molecules25204764 |
Ejemplares similares
-
Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016) -
Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022) -
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021) -
Radiolabeled Antibodies for Cancer Imaging and Therapy
por: Parakh, Sagun, et al.
Publicado: (2022) -
Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
por: Balasubramanian, Adithya, et al.
Publicado: (2020)